Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | POLA1 | P09884 | 1/20 | 0.77 |
| ▸ | POLG | P54098 | 1/20 | 0.77 |
| ▸ | HPRT1 | P00492 | 13/20 | 0.71 |
| ▸ | PNP | P00491 | 6/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gs-438 SCHEMBL3497651 | 0.96 | POLB (0.84) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL8905164 | 0.93 | HPRT1 (0.72) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL9053832 | 0.92 | HPRT1 (0.74) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL8905172 | 0.92 | HPRT1 (0.71) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL2734697 | 0.91 | POLB (0.77) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL15545141 | 0.90 | HPRT1 (0.81) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL8896276 | 0.90 | HPRT1 (0.81) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL24721833 | 0.89 | POLB (0.74) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL9055784 | 0.89 | POLB (0.81) | POLBPOLA1POLGHPRT1PNP | |
| SCHEMBL8898386 | 0.89 | HPRT1 (0.80) | POLBPOLA1POLGHPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731002-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2026-04-29 | — | — | EP | claimed |
| US-12497435-B2 | Multimerization of IL-15/IL-15R-alpha-fc complexes to enhance immunotherapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | claimed |
| US-12404332-B2 | Methods for diagnosing and treating cancers | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-09-02 | — | — | US | claimed |
| WO-2024263793-A2 | SYSTEMS FOR PRODUCTION OF PRODUCTS TO PROMOTE NITROGEN USE EFFICIENCY IN PLANTS | Tenfold Technologies, LLC (US) | 2024-12-26 | — | — | WO | claimed |
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| US-20220106375-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | claimed |
| EP-3908314-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2021-11-17 | — | — | EP | claimed |
| US-6964968-B2 | Method for the treatment or prevention of viral infection using nucleoside analogues | SHIRE BIOCHEM, INC. (CA) | 2005-11-15 | — | — | US | claimed |
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | US ARMY, SECRETARY OF THE ARMY | 2005-09-01 | — | — | US | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6583149-B1 | 2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-Dioxolane | BIOCHEM PHARMA INC. (CA) | 2003-06-24 | — | — | US | claimed |
| US-6093816-A | Cationic lipids | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| WO-1996040704-A1 | PYRAZOLE-RELATED DERIVATIVES ENDOWED WITH ANTITUMOR AND ANTIVIRAL ACTIVITIES, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM | SARDINIAN ANTIVIRAL RESEARCH CONSORTIUM SARC S.C.R.L. (IT) | 1996-12-19 | — | — | WO | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | POLB 270/4885POLA1 422/4885POLG 480/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | POLB 84/4885POLA1 31/4885POLG 263/4885 |
| US-20050192246-A1 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | PHPT1, PPIP5K2, PHOSPHO1 | POLB 621/4885POLA1 1353/4885POLG 933/4885 |
| US-12404332-B2 | Methods for diagnosing and treating cancers | CHEK1, CHEK2, MRE11 | POLB 248/4885POLA1 449/4885POLG 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.